Navigation Links
Vasogen Provides an Update on ACCLAIM-II Preparations
Date:12/17/2007

MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today provided an update on ACCLAIM-II, a confirmatory clinical trial which is designed to support an application for US market approval of the Celacade(TM) System for the treatment of patients with NYHA Class II heart failure.

The Company has been working diligently on the ACCLAIM-II study, including the establishment of a Steering Committee led by James B. Young, MD, Chairman, Division of Medicine at the Cleveland Clinic Foundation and Medical Director, Kaufman Center for Heart Failure; appointing Chairs for the Data and Safety Monitoring Board (DSMB) and Central Endpoint Committee (CEC); developing the study protocol, CEC adjudication plans, and other key trial documents, such as case report forms and informed consent forms; and selecting a contract research organization to assist with study execution.

Concurrent with the preparations for ACCLAIM-II, Vasogen has been working closely with the U.S. Food and Drug Administration (FDA) to finalize the protocol and the statistical analysis plan for the study using a Bayesian approach and adaptive clinical design. The planned study design indicates that as few as 300 patients could provide sufficient data to confirm the finding in the pre-specified sub-group of ACCLAIM patients with NYHA Class II heart failure. Furthermore, the use of an adaptive clinical trial design also provides the flexibility to increase the sample size up to 600 patients, should additional data be required. The ACCLAIM trial demonstrated a 39% reduction (p=0.0003) in the risk of death and cardiovascular hospitalizations for the large pre-specified subgroup of 689 NYHA class II heart failure patients.

In preparation
'/>"/>

SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. CardioDynamics Provides 2007 Shareholder Meeting Update
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. NxStage Medical Provides Update on Medisystems Acquisition
7. VaxGen Files 2006 Financial Statements and Provides Cash Update
8. Signalife Provides Corporate Update
9. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
10. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
11. SGX Provides Update on BCR-ABL Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider of ... and medical device industries, has announced a laboratory and ... has consolidated its histology and tissue analysis operations from ... just north of Denver. The new addresses are: ... Suite 100, Westminster, CO 80021 , Tissue Image Analysis ...
(Date:8/27/2014)... 27, 2014 Riviera Beach, Florida ... the creation of the Sancilio Scientific Advisory Board ... SCI’s philosophy of looking to nature for pharmaceutical ... actions are based on sound scientific data, analyses, ... Board provides a vehicle for SCI to receive ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 WriteResult, ... services – has once again shown superiority when it ... sponsor by completing the ePRO portion of their most ... The Japan-based pharma chose WriteResult’s digital writing platform ... trials – the first to complete drew data from ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed data of ... virus strains has revealed extensive conservation and sharing of ... sharing of specific Replikin gene structures has permitted the ... did for the H5N1 influenza vaccine and the Taura ... to be effective (1,2). This ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot ... replaces Dr. Gregory Stock who will continue to remain active ... , , ... to Signum an outstanding track record of success in growing value at ...
... to conduct the study at the Norris Comprehensive Cancer Center of ... , , ... - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ... endocrine therapy, today announced that the National Institutes of Health ("NIH") has ...
... Aug. 4 Forte, LLC, today announced ... probate database and estate recovery application that significantly ... OnDemand provides access to a proprietary database of ... matching algorithms that accurately match deceased accounts to ...
Cached Biology Technology:Signum Biosciences Names Braham Shroot as Chief Executive Officer 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 3Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 4Forte Launches Probate Finder OnDemand™ 2Forte Launches Probate Finder OnDemand™ 3
(Date:8/27/2014)... CHICAGO , Aug. 27, 2014 /PRNewswire-iReach/ -- The ... hosting the 36 th Annual International Conference (EMBC,14), ... and Towers in Chicago, Illinois , ... than 2,500 global leaders, students, and industry professionals in ... Logo - http://photos.prnewswire.com/prnh/20140827/140333 ...
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
(Date:8/27/2014)... the main factors thought to be associated with ... are the age of the patient, mechanism of ... time, repair method, operation technique, and repair materials. ... repair of peripheral nerve injuries, there is no ... prognosis, and the dose-effect relationship of the predictors ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3New study throws into question long-held belief about depression 2
... are urgently needed in resource-limited countries. A ... Microbiology colloquium, "Bringing the Lab to the Patient: ... the challenges inherent in bringing new medical devices ... where they are needed most. Point-of-care diagnostics (POCTs) ...
... helped open a new door of possibility in the high-stakes ... an international team, the scientists including Stanford Woods Institute ... found a way to create future ocean conditions in a ... the device can mimic the composition of the future ocean ...
... world dolomite is quite common. More than 90 percent of ... first described scientifically in the 18th century. But who would ... not fully understood, although geologists are aware of large deposits ... years. The process of recent primary dolomite formation is restricted ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2Stanford researchers help predict the oceans of the future with a mini-lab 2How does dolomite form? 2
... The ImageXpressULTRA imaging system ... true point-scanning confocal system for automated ... high throughput cell-based screening. ImageXpressULTRA ... software solution for screening acquisition, image ...
... Assay is an anchorage-independent growth assay in ... stringent assay for detecting malignant transformation of ... with carcinogens or carcinogen inhibitors) are cultured ... for 21-28 days. Following this incubation ...
... The BD CARV II Confocal Imager ... an easy to use and cost effective ... microscope. High speed multi-point confocal scanning, combined ... photobleaching and allows real-time imaging and recording ...
... Gels easier and more efficient by providing ... types of pre-cut pre-assembled membrane/filter paper sandwiches ... cm E-PAGE Gels*. The available nitrocellulose and ... transfer of proteins (Figure 1 Table 1). ...
Biology Products: